These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11890186)

  • 21. Controlled comparison of two different doses of milnacipran in major depressive outpatients.
    Kanemoto K; Matsubara M; Yamashita K; Tarao Y; Inada E; Sekine T
    Int Clin Psychopharmacol; 2004 Nov; 19(6):343-6. PubMed ID: 15486520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
    Isaac MT; Isaac MB; Gallo F; Tournoux A
    Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
    Kiev A; Feiger A
    J Clin Psychiatry; 1997 Apr; 58(4):146-52. PubMed ID: 9164424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients.
    Guelfi JD; Ansseau M; Corruble E; Samuelian JC; Tonelli I; Tournoux A; Plétan Y
    Int Clin Psychopharmacol; 1998 May; 13(3):121-8. PubMed ID: 9690979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial.
    Rossini D; Serretti A; Franchini L; Mandelli L; Smeraldi E; De Ronchi D; Zanardi R
    J Clin Psychopharmacol; 2005 Oct; 25(5):471-5. PubMed ID: 16160624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C
    Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients.
    Sugawara Y; Higuchi H; Yoshida K; Takahashi H; Kamata M; Naito S; Sato K; Shimizu T
    Clin Neuropharmacol; 2006; 29(1):6-9. PubMed ID: 16518126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptoms of agitated depression and/or akathisia.
    Peitl MV; Prološčić J; Blažević-Zelić S; Skarpa-Usmiani I; Peitl V
    Psychiatr Danub; 2011 Mar; 23(1):108-10. PubMed ID: 21448111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.
    Hochberg HM; Kanter D; Houser VP
    Pharmacopsychiatry; 1995 Nov; 28(6):253-6. PubMed ID: 8773292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
    Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH
    Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of milnacipran by risperidone in treatment for major depression.
    Tani K; Takei N; Kawai M; Suzuki K; Sekine Y; Toyoda T; Minabe Y; Mori N
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):55-8. PubMed ID: 14731310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
    Okumura K; Furukawa TA
    Clin Drug Investig; 2006; 26(3):135-42. PubMed ID: 17163244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
    Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M
    J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Milnacipran: new preparation. Tricyclics remain first-line antidepressants.
    Prescrire Int; 1998 Apr; 7(34):51-3. PubMed ID: 10183385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients.
    Ansseau M; von Frenckell R; Mertens C; de Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P; Dejaiffe G
    Psychopharmacology (Berl); 1989; 98(2):163-8. PubMed ID: 2569214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group.
    Rouillon F; Warner B; Pezous N; Bisserbe JC
    Int Clin Psychopharmacol; 2000 May; 15(3):133-40. PubMed ID: 10870871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.